American College of Cardiology (ACC)

The American College of Cardiology (ACC) is the primary U.S. medical society representing the interests of all cardiology subspecialities. The ACC is very active in setting guidelines for cardiac care, lobbying for supportive government policy and reimbursements, clinician education, managing several key cardiovascular registries and advocating for the transformation of cardiovascular care to improve heart health.

IVL may be safer than atherectomy in patients with severely calcified lesions
Researchers explored data from more than 1,000 patients with calcified coronary artery disease who required plaque modification. IVL and atherectomy were linked to comparable success rates, but adverse events were less likely with IVL.
Joint Commission partners with STS, ACC on new cardiac care certification
The new certification is focused on the importance of high-quality care and real-world patient outcomes. It will be based on the same data care teams already submit if they participate in the STS Adult Cardiac Surgery Database, ACC CathPCI Registry or STS/ACC TVT Registry.
FDA-approved PFA system linked to positive 1-year data, ‘impeccable’ durability
The Globe Pulsed Field System, which secured FDA approval in September 2025, features high-density mapping capabilities and a 122-electrode spherical array.
Treating CLTI with atherectomy fails to improve outcomes—is it worth the cost?
Atherectomy is associated with rising healthcare costs, making it important to learn as much about the procedure's long-term value as possible.
Medical societies, medtech companies and clinicians weigh in as CMS considers sweeping TAVR changes
CMS is considering substantial updates to its TAVR policies, including coverage for asymptomatic patients. Some stakeholders are excited, embracing the possibility of expanded indications and fewer restrictions. Others are concerned that the changes would be too much, too soon.

Newsweek ranked the 50 best heart hospitals in the world

ACC.24: TAVR linked to lower 1-year mortality, stroke rates than SAVR in low-risk patients

TAVR is noninferior to SAVR when treating low-risk patients, according to new data presented at ACC.24. In fact, it is associated with multiple benefits over surgery.

ACC.24 sign American College of Cardiology

ACC.24: Impella CP boosts survival for patients with STEMI-related cardiogenic shock

“This is the first time in a very long time that we have a positive study for managing cardiogenic shock,” one cardiologist said.

ACC.24: Self-expanding Evolut valves offer superior performance for TAVR patients with small annuli

The SMART trial included one-year data from TAVR patients randomized to receive either a self-expanding Evolut valve or a balloon-expandable Sapien 3 valve. All patients presented with symptomatic severe aortic stenosis and a small aortic annulus. A whopping 87% of participants were women.

semaglutide wegovy Novo Nordisk major adverse cardiovascular events

Weight loss drug semaglutide benefits obese patients presenting with HFpEF, type 2 diabetes

The new research, based on data from more than 600 patients, was presented at ACC.24 in Atlanta and published in the New England Journal of Medicine. Semaglutide is sold by Novo Nordisk under the brand name Wegovy.

ACC.24, the annual meeting of the American College of Cardiology (ACC), kicked off on Saturday, April 6, with a series of late-breaking clinical trials focused on testing the safety and effectiveness of new treatment strategies.

Day 1 at ACC.24: Late-breakers examine potential new heart attack, heart failure treatments

ACC.24 in Atlanta began Saturday, April 6, with a series of late-breaking clinical trials exploring brand new treatment strategies.

Transcatheter pulmonary valve replacement (TPVR) with Medtronic’s self-expanding Harmony valve is both safe and effective after more than a year, according to new real-world data published in the Journal of the American College of Cardiology.[1]

TPVR with self-expanding Harmony valve associated with ‘excellent’ real-world outcomes

Transcatheter pulmonary valve replacement is still linked to certain risks, researchers noted, but new data confirm it is a safe, effective treatment option for patients with severe PR.

Osso VR, a San Francisco-based virtual reality (VR) company, has developed a new VR training simulation focused on left atrial appendage occlusion (LAAO) procedures. The simulation is designed to offer clinicians a new way to practice LAAO procedures in a “repeatable, risk-free virtual environment.”

Cardiologist-approved VR for interventional procedures headed to ACC.24

San Francisco-based Osso VR and the American College of Cardiology have collaborated on advanced LAAO simulations. The two groups first started working together back in 2022.

GE Healthcare has announced the upcoming launch of new artificial intelligence (AI) software compatible with the company’s Vscan Air SL handheld ultrasound system.

GE Healthcare launching new AI software for handheld ultrasound system

The company's new AI offering, a product of its 2023 acquisition of Caption Health, will make its debut at ACC.24 in Atlanta.

American College of Cardiology (ACC)

IVL may be safer than atherectomy in patients with severely calcified lesions

Joint Commission partners with STS, ACC on new cardiac care certification

FDA-approved PFA system linked to positive 1-year data, ‘impeccable’ durability

Treating CLTI with atherectomy fails to improve outcomes—is it worth the cost?

Medical societies, medtech companies and clinicians weigh in as CMS considers sweeping TAVR changes